98%
921
2 minutes
20
Objective: The aim of this study was to verify the association among obstructive sleep apnea, functional capacity, and metabolic control.
Methods: This was a cross-sectional study involving individuals of both sexes with clinical diagnosis of diabetes mellitus type 2 who were above 18 years of age. The assessment consisted of a volunteer identification form, a 2-minute step test, and the Stop-Bang questionnaire. In order to assess metabolic control, HbA1c and fasting glucose data were collected from medical records.
Results: A total of 100 individuals with diabetes mellitus type 2, of whom 61% were women, were included in this study. According to the Stop-Bang instrument, 26, 57, and 17% of patients had low, intermediate, and high risk of developing OSA, respectively. There was no association between the 2-minute step test and metabolic variables and diabetes mellitus type 2 chronicity with Stop-Bang.
Conclusions: We concluded that there is no association among obstructive sleep apnea measured by means of Stop-Bang instrument, functional capacity measured by means of 2-minute step test, and metabolic variables in individuals with diabetes mellitus type 2.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1590/1806-9282.20210232 | DOI Listing |
Endocrine
September 2025
Section of Endocrinology, Geriatrics and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Apoptosis
September 2025
The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, 182 Chunhui Road, Longmatan District, Luzhou, 646000, China.
Diabetic cardiomyopathy (DCM) is a severe cardiovascular complication of diabetes mellitus, characterized by pathological changes such as cardiomyocyte hypertrophy, necrosis, and myocardial fibrosis, which can ultimately lead to heart failure. However, its underlying mechanisms remain incompletely understood, limiting the development of effective therapeutic approaches. In recent years, the critical roles of oxidative stress and ferroptosis in the pathogenesis of DCM have attracted increasing attention.
View Article and Find Full Text PDFDiabetologia
September 2025
Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany.
Arch Gynecol Obstet
September 2025
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Objective: To investigate adverse pregnancy and delivery outcomes in women with GDMA1 during pregnancies conceived through fertility treatments.
Methods: This population-based retrospective cohort study examined adverse pregnancy and delivery outcomes in pregnancies affected by GDMA1 following fertility treatments compared to those conceived naturally. Women with GDMA1 who conceived via fertility treatments were classified as cases, while those who conceived naturally were designated as controls.
Minerva Cardiol Angiol
September 2025
Department of Pharmacology, MGM Medical College and Hospital, MGM Institute of Health Sciences, Nerul, Navi Mumbai, India.
Liraglutide is a key therapeutic agent in managing type 2 diabetes mellitus (T2DM), with benefits extending beyond glycemic control to address cardiovascular and renal comorbidities. As T2DM prevalence rises globally, the need for medications that provide comprehensive health benefits becomes increasingly important. Liraglutide, a GLP-1 receptor agonist, has demonstrated effectiveness in reducing cardiovascular events, especially among patients with high cardiovascular risk, such as those with a prior history of myocardial infarction or stroke.
View Article and Find Full Text PDF